Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
si-CRISP3 is a small interfering RNA (siRNA) designed to silence the expression of the Cysteine-Rich Secretory Protein 3 (CRISP3) gene. In the context of prostate cancer research, CRISP3 has been identified as a critical factor that promotes tumor cell proliferation and metastasis by inducing the epithelial-to-mesenchymal transition (EMT). By targeting CRISP3 mRNA for degradation, si-CRISP3 inhibits these oncogenic processes, making it a valuable tool for studying the molecular mechanisms of bone metastatic prostate cancer and a potential candidate for RNA-based therapeutic strategies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on si-CRISP3.